EFFECT OF AGE ON PROGNOSIS IN DIFFERENT MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA

Naveed Sharif, Sajjad Ahmad, Muhammad Mumtaz Khan, Ahmareen Khalid, Sadaf Alam, Sara Ziaullah, Sabeen Nasir, Fozia Rauf

Abstract


Background: Breast carcinoma is one of the ten commonest worldwide malignancies. The objective of the
current study was to correlate the significance of prognostic markers and molecular subtypes with patients’ age
in carcinoma of female breast.
Material & Methods: A descriptive study was conducted at Department of Pathology, Peshawar Medical College,
Peshawar and Pakistan Institute of Medical Sciences, Islamabad. Sixty mastectomy specimens were selected
using a non-probability sampling method from 1st January, 2012 to 31st December, 2013. Histological type, tumor
size, tumor grade and lymph node status were determined. Estrogen receptor (ER), progesterone receptor (PR)
and Her-2/neu expression were evaluated immunohistochemically.
Results: Among these 60 patients, the mean age was 50.5±14.4 years. There were 26 (43.3%) patients with age
more than 50 years while 24 (40%) were between 40 and 50 years. Ten (16.7%) patients had age less than 40
years. Luminal A molecular subtype was observed in 50% in age groups 40 to 50 and above 50 years. The age
group above 50 years had more cases of luminal B (58%) and non-luminal (42%) types. Triple negative molecular
subtype is more common in age group between 40 and 50 years i.e. 57.1%.
Conclusions: It was concluded that age is an important factor in determining the aggressiveness of female breast
cancer along with other markers like, ER, PR and HER2/neu receptor status.

Keywords


Invasive ductal carcinoma, Estrogen receptor, Progesterone receptor, Her2neu

Full Text:

PDF

References


Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-907.

Aziz Z, Sana S, Saeed S, Akram M. Institution based tumor registry from Punjab: five year data based analysis. J Pak Med Assoc 2003; 53: 350-3.

Leong SPL, Shen Z-Z, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg 2010; 34: 2308-24.

Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.

Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 2009; 208: 341-7.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.

McCarty KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46 (8 Suppl): 4244s-4248s.

Viale G. The current state of breast cancer classification. Ann Oncol 2012; 23 Suppl 10: 207-10.

Jamal S, Moghal S, Mamoon N, Mushtaq S, Luqman M, Anwar M. The pattern of malignant tumours: tumour registry data analysis, AFIP, Rawalpindi, Pakistan (1992-2001). J Pak Med Assoc 2006; 56: 359-62.

Hanif M, Zaidi P, Kamal S, Hameed A. Institution-based cancer incidence in a local population in Pakistan: nine year data analysis. Asian Pac J Cancer Prev 2009; 10: 227-30.

Lester SC. The Breast. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbin and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia, PA 19103-2899: Saunders; 2010. p. 1144-7.

Ross JS, Slodkowska E a, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-68.

Köninki K, Tanner M, Auvinen A, Isola J. HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res 2009; 11: 37.

Mostafa M, Larsen M, Love R. Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women. J Bangladesh Coll Phys Surg 2010; 28: 157-62.

Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of HER-2/ neu status in breast cancer using fluorescence in situ hybridization and immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian J Med Res 2010; 132: 287-94.

Keyhani E, Muhammadnejad A, Karimlou M. Prevalence of HER-2-positive invasive breast cancer: a systematic review from Iran. Asian Pac J Cancer Prev 2012; 13: 5477-82.

Anderson WF, Katki H a, Rosenberg PS. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 2011; 103: 1397-402.

Chung S, Park SK, Sung H, Song N, Han W, Noh D-Y, et al. Association between chronological change of reproductive factors and breast cancer risk defined by hormone receptor status: results from the Seoul Breast Cancer Study. Breast Cancer Res Treat 2013; 140: 557-65.

Kamil M, Khalid I, Hashim H, Biswas M, Kaur G, et al. Association of carcinoma breast: grade and estrogen progesterone receptor expression. J Coll Physicians Surg Pak 2010; 20: 250-2.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT, Jamal S. Steroid hormone receptor association with prognostic markers in breast carcinoma in Northern Pakistan. J Coll Physicians Surg Pak 2010; 20: 181-5.

Arpino G, Weiss H, Lee A V, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 1254-61.

Rakha EA, El-Sayed ME, Lee AHS, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008; 26: 3153-8.

Albrektsen G, Heuch I, Thoresen SØ. Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway. BMC Cancer 2010; 10: 226.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT. Age related association of Her-2/neu with prognostic markers in female breast carcinoma. J Coll Physicians Surg Pak 2010; 20: 590-4.

Nisa A, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008; 9: 553-6.

Ishaque N. Her 2 Overexpression in Breast Carci¬noma; Its Significance and Association with Age and Tumor Grade. Ann Pak Inst Med Sci 2014; 10: 54-6.

Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz V, Visscher D, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res 2013; 15: 104.

Wildiers H, Van Calster B, van de Poll-Franse L V, Hendrickx W, Røislien J, Smeets A, et al. Relationship between age and axillary lymph node involvement in women with breast cancer. J Clin Oncol 2009; 27: 2931-7.

Pirone JR, D’Arcy M, Stewart DA, Hines WC, Johnson M, Gould MN, et al. Age-associated gene expression in normal breast tissue mirrors qualitative age-at-incidence patterns for breast cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1735-44.

Sajid MT, Ahmed M, Azhar M, Mustafa Q, Shukr I, Kamal Z. Age-related frequency of triple negative breast cancer in women. J Coll Physicians Surg Pak 2014; 24: 400-3.

Hashmi AA, Edhi MM, Naqvi H, Faridi N, Khurshid A, Khan M. Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol 2014; 9: 43.

Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer 2010; 116: 2549-59.

Clarke C a, Keegan THM, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 2012; 104: 1094-101.

Singh M, Ding Y, Zhang L, Song D, Gong Y, Adams S, et al. Distinct breast cancer subtypes in women with early-onset disease across races. Am J Cancer Res 2014; 4: 337-52.


Refbacks

  • There are currently no refbacks.


Copyright (c)



© 2011 Gomal Journal of Medical Sciences